Bausch & Lomb IOL deal
This article was originally published in The Gray Sheet
Eye care giant gains worldwide rights, excluding Japan, to Santen Pharmaceutical's hydrophobic acrylic polymers, which will be used in the development of intraocular lenses. B&L currently markets IOL products including Crystalens, the only FDA-approved accommodating IOL, Akreos and SofPort. The acquisition of Crystalens maker Eyeonics in 2008 marked B&L's entry into the premium IOL market, in which it competes with Alcon and Abbott subsidiary Advanced Medical Optics (1"The Gray Sheet" Jan. 28, 2008, p. 3)
You may also be interested in...
Bausch & Lomb will enter the fast-growing premium intraocular lens market for the first time through its acquisition of Crystalens maker Eyeonics under a pact announced Jan. 20
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.